Feasibility and effectiveness of chemical bile duct embolization for chemical hepatectomy: a preliminary study.
BACKGROUND
The high operative risk of hepatectomy for specially located intrahepatic stones is still a problem to be solved. This study was undertaken to investigate the feasibility and effectiveness of chemical bile duct embolization for chemical hepatectomy.


METHODS
Oxybenzene or absolute ethanol plus N-butyl-cyanoacrylate was employed for embolization. The feasibility, effectiveness and mechanism of chemical hepatectomy were preliminarily analyzed histologically or by Fas, TIMP-1, TGF-beta(1), and collagen I.


RESULTS
Oxybenzene plus cyanonacrylate can preferably destroy and embolize the intrahepatic biliary duct, leading to the disappearance of hepatocytes in the periphery of embolized lobe and the achievement of effective chemical hepatectomy. The expressions of Fas, TIMP-1 and TGF-beta(1) in oxybenzene embolism group (88.90 +/- 38.10, 619.43 +/- 183.42, 185.22 +/- 70.39) and ethanol embolism group (72.39 +/- 29.51, 407.55 +/- 134.74, 163.56 +/- 51.75) were higher than those of biliary duct-ligated group (26.31 +/- 12.07, 195.31 +/- 107.67, 74.84 +/- 40.73) (P<0.05). The collagen I-positive percentage in the oxybenzene embolism group was also greater than that of the ethanol embolism group (33.97 +/- 12.51% vs. 20.67 +/- 8.09%, P<0.05).


CONCLUSIONS
The effect of chemical hepatectomy may be achieved by chemical bile duct embolization.
Li
Fu-Yu
FY
Department of Hepatobiliary Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Li
Ning
N
Jiang
Li-Sheng
LS
Cheng
Jing-Qiu
JQ
Cheng
Nan-Sheng
NS
Wu
Xing-Wu
XW
He
Sheng
S
D000818:Animals; D001652:Bile Ducts / Q000187:drug effects; D002137:Calculi / Q000628:therapy*; D024042:Collagen Type I / Q000378:metabolism; D004621:Embolization, Therapeutic / Q000379:methods*; D000431:Ethanol / Q000494:pharmacology*; D053222:Fas Ligand Protein / Q000378:metabolism; D006498:Hepatectomy / Q000379:methods; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D019800:Phenol / Q000494:pharmacology*; D010865:Pilot Projects; D051381:Rats; D017207:Rats, Sprague-Dawley; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
D024042:Collagen Type I; D053222:Fas Ligand Protein; D019715:Tissue Inhibitor of Metalloproteinase-1; D053773:Transforming Growth Factor beta1; D019800:Phenol; D000431:Ethanol